211 related articles for article (PubMed ID: 32274887)
1. Emerging strategies to treat rare and intractable subtypes of melanoma.
Alicea GM; Rebecca VW
Pigment Cell Melanoma Res; 2021 Jan; 34(1):44-58. PubMed ID: 32274887
[TBL] [Abstract][Full Text] [Related]
2. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.
Elder DE; Bastian BC; Cree IA; Massi D; Scolyer RA
Arch Pathol Lab Med; 2020 Apr; 144(4):500-522. PubMed ID: 32057276
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of melanoma aggressiveness with age.
Bertolotto C
Nat Aging; 2024 Mar; 4(3):287-288. PubMed ID: 38472453
[No Abstract] [Full Text] [Related]
5. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.
Basurto-Lozada P; Molina-Aguilar C; Castaneda-Garcia C; Vázquez-Cruz ME; Garcia-Salinas OI; Álvarez-Cano A; Martínez-Said H; Roldán-Marín R; Adams DJ; Possik PA; Robles-Espinoza CD
Pigment Cell Melanoma Res; 2021 Jan; 34(1):59-71. PubMed ID: 32330367
[TBL] [Abstract][Full Text] [Related]
6. Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.
Chacón M; Pfluger Y; Angel M; Waisberg F; Enrico D
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825562
[TBL] [Abstract][Full Text] [Related]
7. Progress in melanoma treatment: Patient's perspectives.
Alicea GM; Villanueva J; Webster MR; Rebecca VW
Pigment Cell Melanoma Res; 2023 Nov; 36(6):594-601. PubMed ID: 37819777
[TBL] [Abstract][Full Text] [Related]
8. Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.
Simiczyjew A; Wądzyńska J; Kot M; Ziętek M; Matkowski R; Hoang MP; Donizy P; Nowak D
J Cell Mol Med; 2023 Oct; 27(19):2995-3008. PubMed ID: 37679999
[TBL] [Abstract][Full Text] [Related]
9. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.
Castellani G; Buccarelli M; Arasi MB; Rossi S; Pisanu ME; Bellenghi M; Lintas C; Tabolacci C
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627054
[TBL] [Abstract][Full Text] [Related]
10. Experimental Models for Rare Melanoma Research-The Niche That Needs to Be Addressed.
Ionita I; Malita D; Dehelean C; Olteanu E; Marcovici I; Geamantan A; Chiriac S; Roman A; Radu D
Bioengineering (Basel); 2023 Jun; 10(6):. PubMed ID: 37370604
[TBL] [Abstract][Full Text] [Related]
11. Management of Advanced Invasive Melanoma: New Strategies.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Fornaro L; Martora F; Potestio L
Adv Ther; 2023 Aug; 40(8):3381-3394. PubMed ID: 37306810
[TBL] [Abstract][Full Text] [Related]
12. Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.
Zhu J; Li X; Gao W; Jing J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835282
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.
Tanaka Y; Ito T; Kaku-Ito Y; Tanegashima K; Tsuji G; Kido-Nakahara M; Oda Y; Nakahara T
Cell Death Discov; 2023 Feb; 9(1):54. PubMed ID: 36765036
[TBL] [Abstract][Full Text] [Related]
14. RAS pathway regulation in melanoma.
Al Mahi A; Ablain J
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35234863
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Hayward NK; Pritchard AL
Pigment Cell Melanoma Res; 2022 May; 35(3):369-386. PubMed ID: 35229492
[TBL] [Abstract][Full Text] [Related]
16. Un-Fair Skin: racial disparities in acral melanoma research.
Alicea GM; Rebecca VW
Nat Rev Cancer; 2022 Mar; 22(3):127-128. PubMed ID: 35075287
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.
Ma Y; Xia R; Ma X; Judson-Torres RL; Zeng H
Front Oncol; 2021; 11():702287. PubMed ID: 34350118
[TBL] [Abstract][Full Text] [Related]
18. No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma.
Safi M; Trapani D; Alradhi M; Shan X; Jiwei L
Pathol Oncol Res; 2021; 27():639004. PubMed ID: 34257604
[No Abstract] [Full Text] [Related]
19. Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.
Han A; Schug ZT; Aplin AE
Trends Cancer; 2021 Aug; 7(8):671-681. PubMed ID: 34127435
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Clinicopathological Significance of
González-Ruiz L; González-Moles MÁ; González-Ruiz I; Ruiz-Ávila I; Ramos-García P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
